ReviewTechnology in cancer research & treatment
Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology.
Review in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors impose a substantial burden on global health, with an urgent unmet need for effective targets to advance precision therapy. As evolutionarily conserved microtubule motor proteins, the kinesin family (KIF) orchestrates fundamental cellular processes (e.g., intracellular transport, cell division) and canonical signaling pathways, including Wnt and Hippo. Notably, recent studies have uncovered their emerging role in regulating tumor metabolism and reshaping the immune microenvironment, where dysregulated KIF expression drives aberrant tumor proliferation. Based on current research, here we synthesize the latest mechanistic insights into KIF-mediated tumor regulation and evaluate their translational potential as next-generation therapeutic targets and biomarkers for precision cancer therapy. KIF-targeted inhibitors have entered clinical trials across multiple cancer types, holding promise as novel anticancer agents to suppress tumor growth and progression, thereby providing valuable therapeutic options for clinical oncology practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.